Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enzymatic Therapy Takes Back Distribution Rights for Remifemin - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Enzymatic Therapy Takes Back Distribution Rights for Remifemin

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Enzymatic Therapy, Green Bay, WI, has re-acquired the distribution rights for Remifemin, a leading OB/GYN-recommended, non-prescription menopausal therapy. The company was first to handle the brand’s distribution from 1995 to 2000. Then, Remifemin distribution went to GlaxoSmithKline Consumer Healthcare as the product entered mass markets. Now with Enzymatic Therapy’s recent growth and distribution acquisitions for Alluna, SneezEze and Renouvelle, the company said the timing was right for it to reacquire Remifemin. The transaction became effective June 20th when rights for the product were transferred. Enzymatic Therapy has partnered with Shaper & Brummer, GmbH & Co. KG, the German manufacturer of Remifemin, to increase product distribution and market share. The company will also be implementing practitioner and consumer education programs.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters